Brandon Moss

582 total citations
26 papers, 311 citations indexed

About

Brandon Moss is a scholar working on Pathology and Forensic Medicine, Neurology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Brandon Moss has authored 26 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 8 papers in Neurology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Brandon Moss's work include Multiple Sclerosis Research Studies (17 papers), Peripheral Neuropathies and Disorders (7 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Brandon Moss is often cited by papers focused on Multiple Sclerosis Research Studies (17 papers), Peripheral Neuropathies and Disorders (7 papers) and Sarcoidosis and Beryllium Toxicity Research (5 papers). Brandon Moss collaborates with scholars based in United States, Switzerland and Italy. Brandon Moss's co-authors include Jeffrey A. Cohen, Carrie M. Hersh, Mary Rensel, Marisa McGinley, Daniel A. Culver, Mary Alissa Willis, Bassem Allam, Daniel Ontaneda, Laura Baldassari and Gabrielle Macaron and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Annals of Neurology.

In The Last Decade

Brandon Moss

21 papers receiving 307 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brandon Moss United States 12 163 93 55 42 39 26 311
Tamara Kaplan United States 10 161 1.0× 74 0.8× 38 0.7× 57 1.4× 12 0.3× 39 305
Pablo A. López Argentina 12 286 1.8× 171 1.8× 80 1.5× 30 0.7× 10 0.3× 53 449
Jarmila Heissigerová Czechia 12 47 0.3× 82 0.9× 14 0.3× 46 1.1× 26 0.7× 36 382
Yasuhito Nerome Japan 10 35 0.2× 29 0.3× 12 0.2× 117 2.8× 24 0.6× 31 340
Esmeralda Neves Portugal 11 51 0.3× 27 0.3× 7 0.1× 104 2.5× 17 0.4× 37 313
Angelo Acquafredda Italy 11 20 0.1× 29 0.3× 36 0.7× 15 0.4× 25 0.6× 30 385
Elin Engdahl Sweden 13 64 0.4× 26 0.3× 34 0.6× 58 1.4× 3 0.1× 20 343
Sengamedu S. Badrinath India 18 31 0.2× 81 0.9× 23 0.4× 8 0.2× 21 0.5× 30 705
T Takahashi Japan 13 47 0.3× 91 1.0× 7 0.1× 35 0.8× 63 1.6× 39 462
Jean‐Luc Dumas France 10 58 0.4× 26 0.3× 10 0.2× 9 0.2× 129 3.3× 18 380

Countries citing papers authored by Brandon Moss

Since Specialization
Citations

This map shows the geographic impact of Brandon Moss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brandon Moss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brandon Moss more than expected).

Fields of papers citing papers by Brandon Moss

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brandon Moss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brandon Moss. The network helps show where Brandon Moss may publish in the future.

Co-authorship network of co-authors of Brandon Moss

This figure shows the co-authorship network connecting the top 25 collaborators of Brandon Moss. A scholar is included among the top collaborators of Brandon Moss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brandon Moss. Brandon Moss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ungprasert, Patompong & Brandon Moss. (2025). Sarcoidosis of the nervous system: a rare but serious manifestation. Current Opinion in Immunology. 98. 102704–102704.
2.
Amin, Moein, Harvey M. Tucker, Brandon Brown, et al.. (2025). Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Neurodegenerative Disease Management. 15(1). 27–36. 3 indexed citations
3.
4.
Hersh, Carrie M., Moein Amin, Harvey M. Tucker, et al.. (2024). Real-world Effectiveness, Tolerability, and Safety of Ofatumumab at 12-month Follow-up (P9-6.014). Neurology. 102(7_supplement_1).
5.
6.
Calabrese, Cassandra, E. Kirchner, M. Elaine Husni, et al.. (2022). Breakthrough SARS – CoV ‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis. Arthritis & Rheumatology. 74(12). 1906–1915. 22 indexed citations
7.
Lambe, Jeffrey, Marisa McGinley, Brandon Moss, et al.. (2022). Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series. Journal of Neuroimmunology. 370. 577933–577933. 12 indexed citations
8.
Moss, Brandon, et al.. (2022). Exploring the impact of the COVID-19 pandemic on social isolation and mental health in people with MS. Multiple Sclerosis and Related Disorders. 68. 104186–104186. 3 indexed citations
9.
Ungprasert, Patompong, et al.. (2022). Neurosarcoidosis: an update on diagnosis and therapy. Expert Review of Neurotherapeutics. 22(8). 695–705. 3 indexed citations
10.
Vollmer, Timothy, Jeffrey A. Cohen, Enrique Álvarez, et al.. (2020). Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 46. 102454–102454. 15 indexed citations
11.
Grebenciucova, Elena, et al.. (2020). Multiple Sclerosis Disease‐Modifying Therapies in the COVID‐19 Era. Annals of Neurology. 88(6). 1062–1064. 6 indexed citations
12.
Moss, Brandon, et al.. (2019). Evaluating S100B as a serum biomarker for central neurosarcoidosis. Respiratory Medicine. 162. 105855–105855. 13 indexed citations
13.
Baldassari, Laura, Kunio Nakamura, Brandon Moss, et al.. (2019). Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Multiple Sclerosis and Related Disorders. 38. 101525–101525. 15 indexed citations
14.
Moss, Brandon & Jeffrey A. Cohen. (2019). The emergence of follow-on disease-modifying therapies for multiple sclerosis. Multiple Sclerosis Journal. 25(12). 1560–1565. 8 indexed citations
15.
Miller, Deborah, Brandon Moss, Susannah Rose, et al.. (2019). Obtaining Patient Priorities in a Multiple Sclerosis Comprehensive Care Center: Beyond Patient-Reported Outcomes. SHILAP Revista de lepidopterología. 7(4). 541–548. 7 indexed citations
16.
Baldassari, Laura, Gabrielle Macaron, Sarah M. Planchon, et al.. (2019). Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. Multiple Sclerosis Journal - Experimental Translational and Clinical. 5(3). 2454295435–2454295435. 12 indexed citations
17.
Moss, Brandon, Mary Rensel, & Carrie M. Hersh. (2017). Wellness and the Role of Comorbidities in Multiple Sclerosis. Neurotherapeutics. 14(4). 999–1017. 52 indexed citations
18.
Moss, Brandon, et al.. (2017). Neurosarcoidosis. Seminars in Respiratory and Critical Care Medicine. 38(4). 499–513. 28 indexed citations
19.
Moss, Brandon, et al.. (2016). Milling Reliability Curves as Decision-Making Tools in Cased Hole Sidetracking Applications. IADC/SPE Asia Pacific Drilling Technology Conference. 2 indexed citations
20.
Moss, Brandon, et al.. (2006). FLUOROMETRIC MEASUREMENT OF OXIDATIVE BURST IN LOBSTER HEMOCYTES AND INHIBITING EFFECT OF PATHOGENIC BACTERIA AND HYPOXIA. Journal of Shellfish Research. 25(3). 1051–1057. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tamara Kaplan Breakdown of academic impact, for papers by Pablo A. López Breakdown of academic impact, for papers by Jarmila Heissigerová Breakdown of academic impact, for papers by Yasuhito Nerome Breakdown of academic impact, for papers by Esmeralda Neves Breakdown of academic impact, for papers by Angelo Acquafredda Breakdown of academic impact, for papers by Elin Engdahl Breakdown of academic impact, for papers by Sengamedu S. Badrinath Breakdown of academic impact, for papers by T Takahashi Breakdown of academic impact, for papers by Jean‐Luc Dumas
Rankless by CCL
2026